Unlocking the Potential of AffiAB® Antibodies for Biomedical Research and Therapeutics

AffiAB® antibodies, developed by AffiGen, are a powerful tool for researchers and clinicians in the fields of life sciences, diagnostics, and therapeutics. These antibodies are engineered to provide high specificity and sensitivity, enabling accurate detection and quantification of target biomolecules.

AffiAB® antibodies are generated using AffiGen’s proprietary Affimer® technology, which is based on small, robust binding proteins that can be tailored to recognize specific targets with high affinity and selectivity. This technology allows for the creation of AffiAB® antibodies that can bind to a wide range of targets, including proteins, peptides, small molecules, and even whole cells.

One of the key advantages of AffiAB® antibodies is their ability to perform well in a range of applications, such as Western blotting, ELISA, immunohistochemistry, and flow cytometry. They have been used successfully in a variety of research areas, including cancer biology, neurodegenerative diseases, infectious diseases, and cardiovascular disorders.

Overall, AffiAB® antibodies offer researchers and clinicians a versatile and reliable tool for detecting and quantifying target biomolecules in a variety of applications, paving the way for advances in basic research, drug discovery, and clinical diagnostics.